Waltham, Massachusetts — August 22, 2025 — Leads & Copy — Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) announced the closing of its underwritten public offering of 89,234,480 shares of common stock, including the underwriter’s option to purchase an additional 14,423,076 shares, at $0.52 per share. The offering also included pre-funded warrants to purchase 21,342,442 shares at $0.5199 per pre-funded warrant.
The gross proceeds from the offering totaled approximately $57.5 million, before deducting underwriting discounts, commissions, and offering expenses. Cantor acted as sole book-running manager.
The financing was led by RA Capital Management and Janus Henderson Investors, with participation from other healthcare-focused investors.
Invivyd intends to use the net proceeds for trial protocol development, planning, advancement of the VYD2311 clinical program, research and development related to its pipeline programs such as respiratory syncytial virus (RSV) and measles, advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and other general corporate purposes.
The securities were offered pursuant to a shelf registration statement on Form S-3 filed with the SEC. The offering was made by means of a prospectus supplement and accompanying prospectus.
Media Relations:(781) 208-1747, media@invivyd.com; Investor Relations: (781) 208-1747, investors@invivyd.com
Source: Invivyd, Inc.
